← Back to home

Antineutrophil cytoplasmic antibody (ANCA) -associated vasculitis (AAV)

Clinical trials for Antineutrophil cytoplasmic antibody (ANCA) -associated vasculitis (AAV) explained in plain language.

Never miss a new study

Get alerted when new Antineutrophil cytoplasmic antibody (ANCA) -associated vasculitis (AAV) trials appear

Sign up with your email to follow new studies for Antineutrophil cytoplasmic antibody (ANCA) -associated vasculitis (AAV), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Completed 1

New drug MT-2990 tested in rare blood vessel disease

Disease control Completed

This early study looked at a new drug, MT-2990, in 5 people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. The goal was to see if the drug is safe and how it affects disease activity. Researchers measured changes in symptoms, imagin…

Matched conditions: ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA) -ASSOCIATED VASCULITIS (AAV)

Phase 1 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control

Last updated Jun 27, 2026 09:01 UTC

Antineutrophil cytoplasmic antibody (ANCA) -associated vasculitis (AAV)

Get alerted when new Antineutrophil cytoplasmic antibody (ANCA) -associated vasculitis (AAV) trials appear

New drug MT-2990 tested in rare blood vessel disease